Episode 281 - The Future of Closed Loop Diabetes Therapy - Xeris Biopharma and Beta Bionics announce partnership to produce bi-hormonal insulin pump with Paul Edick and Sean Saint
Podcast
Podcaster
Diabetics do amazing things every day that go unnoticed. These are their stories.
Beschreibung
vor 1 Jahr
In this episode of Diabetics doing things, Rob interviews Paul
Edick from Xeris Biopharma and Sean Saint from Beta Bionics. They
discuss the formal partnership announcement between Xeris Biopharma
and Beta Bionics, focusing on the development of a bi-hormonal
insulin pump for diabetes management. The conversation touches on
the challenges and benefits of the partnership, the development
process, and the potential impact on diabetes care. Topics
discussed: 1. Partnership between Xeris Biopharma and Beta Bionics
2. The unique challenges faced by a bihormonal pump compared to
traditional insulin pumps. 3. The formulation process of the pump
and collaboration between Xeris and Beta Bionics. 4. The upcoming
phase 2 and phase 3 clinical trials. 5. The importance of glucagon
in diabetes management and the need for increased awareness and
availability of glucagon. 6. The potential for a fully automated
diabetes therapy experience. 7. The role of technology in reducing
the burden of diabetes management and enhancing quality of life. 8.
The journey towards regulatory approval and commercialization. 9.
The historical context of glucagon use and the evolving perceptions
around its importance. 10. The positive impact of the partnership
on advancing diabetes care and glycemic control. Key takeaways: *
The partnership between Xeris Biopharma and Beta Bionics aims to
develop a bihormonal pump for diabetes management. * The
collaboration involves overcoming unique challenges associated with
incorporating both insulin and glucagon in the pump. * The
development process includes formulation, clinical trials, and
regulatory approval. * The partnership highlights the importance of
increasing awareness and availability of glucagon for diabetes
patients. * The ultimate goal is to provide a hands-off, automated
diabetes therapy experience to improve quality of life for
individuals with diabetes. References: * Xeris Biopharma * Beta
Bionics 00:00 Exploring Inspiring Stories of People with
Diabetes and Industry Announcements 00:18 Exciting
Partnership Announcement: Xeris Biopharma and Beta Bionics Join
Forces for Innovative Diabetes Solution 03:58 Revolutionizing
Diabetes Care with Biohormonal Pump and Xerasol Technology
08:52 Exploring the Future of Glucagon Use and Reducing
Stigma in Diabetes Management 13:41 Revolutionizing Diabetes
Therapy: The Future of Automated Insulin and Glucagon Pump Systems
23:41 Overcoming Fear and Stigma: The Journey with Glucagon
and the Future of Insulin Pumps 25:17 Challenges and
Partnerships in Developing a Bi-Hormonal Pump for Diabetes
Management 30:47 Exciting Innovations in Diabetes Care: A
Look into Bi Hormonal Pumps
Edick from Xeris Biopharma and Sean Saint from Beta Bionics. They
discuss the formal partnership announcement between Xeris Biopharma
and Beta Bionics, focusing on the development of a bi-hormonal
insulin pump for diabetes management. The conversation touches on
the challenges and benefits of the partnership, the development
process, and the potential impact on diabetes care. Topics
discussed: 1. Partnership between Xeris Biopharma and Beta Bionics
2. The unique challenges faced by a bihormonal pump compared to
traditional insulin pumps. 3. The formulation process of the pump
and collaboration between Xeris and Beta Bionics. 4. The upcoming
phase 2 and phase 3 clinical trials. 5. The importance of glucagon
in diabetes management and the need for increased awareness and
availability of glucagon. 6. The potential for a fully automated
diabetes therapy experience. 7. The role of technology in reducing
the burden of diabetes management and enhancing quality of life. 8.
The journey towards regulatory approval and commercialization. 9.
The historical context of glucagon use and the evolving perceptions
around its importance. 10. The positive impact of the partnership
on advancing diabetes care and glycemic control. Key takeaways: *
The partnership between Xeris Biopharma and Beta Bionics aims to
develop a bihormonal pump for diabetes management. * The
collaboration involves overcoming unique challenges associated with
incorporating both insulin and glucagon in the pump. * The
development process includes formulation, clinical trials, and
regulatory approval. * The partnership highlights the importance of
increasing awareness and availability of glucagon for diabetes
patients. * The ultimate goal is to provide a hands-off, automated
diabetes therapy experience to improve quality of life for
individuals with diabetes. References: * Xeris Biopharma * Beta
Bionics 00:00 Exploring Inspiring Stories of People with
Diabetes and Industry Announcements 00:18 Exciting
Partnership Announcement: Xeris Biopharma and Beta Bionics Join
Forces for Innovative Diabetes Solution 03:58 Revolutionizing
Diabetes Care with Biohormonal Pump and Xerasol Technology
08:52 Exploring the Future of Glucagon Use and Reducing
Stigma in Diabetes Management 13:41 Revolutionizing Diabetes
Therapy: The Future of Automated Insulin and Glucagon Pump Systems
23:41 Overcoming Fear and Stigma: The Journey with Glucagon
and the Future of Insulin Pumps 25:17 Challenges and
Partnerships in Developing a Bi-Hormonal Pump for Diabetes
Management 30:47 Exciting Innovations in Diabetes Care: A
Look into Bi Hormonal Pumps
Weitere Episoden
vor 4 Monaten
In Podcasts werben
Kommentare (0)